10-Q: BridgeBio Pharma Q3 2025: Attruby Sales Drive Revenue Growth

BridgeBio Pharma reports significant revenue growth in Q3 2025 driven by strong Attruby sales and strategic licensing milestones, despite continued net losses.

Summary

• Net product revenue for the three months ended September 30, 2025, was $108,111 thousand, and $216,351 thousand for the nine months ended September 30, 2025, following FDA approval of Attruby in November 2024.
• Total revenues, net, increased by $117,968 thousand to $120,700 thousand for the three months ended September 30, 2025, compared to $2,732 thousand in the same period in 2024.
• Total revenues, net, increased by $131,878 thousand to $347,898 thousand for the nine months ended September 30, 2025, compared to $216,020 thousand in the same period in 2024.
• Net loss for the three months ended September 30, 2025, was $(184,937) thousand, compared to $(164,254) thousand in the prior year.
• Net loss for the nine months ended September 30, 2025, was $(538,303) thousand, compared to $(275,958) thousand in the same period in 2024.
• Research and development (R&D) expenses decreased by $7,570 thousand for the three months ended September 30, 2025, and $40,575 thousand for the nine months ended September 30, 2025, primarily due to reprioritization of R&D programs.
• Selling, general and administrative (SG&A) expenses increased significantly by $68,802 thousand for the three months ended September 30, 2025, and $178,991 thousand for the nine months ended September 30, 2025, driven by commercial launch activities for Attruby.
• Repaid the Amended Financing Agreement term loan of $467,000 thousand in February 2025 using proceeds from the issuance of $575,000 thousand in 1.75% convertible senior notes due 2031 (2031 Notes).
• Entered into a Royalty Interest Purchase and Sale Agreement in June 2025, selling certain royalty rights on acoramidis net sales in the EU for $300,000 thousand cash.
• European Commission (EC) approved Beyonttra (acoramidis) for ATTR-CM in the EU on February 10, 2025.
• Japanese Ministry of Health, Labour and Welfare approved Beyonttra for ATTR-CM in Japan on March 27, 2025, with pricing approval on May 21, 2025.
• UK Medicines and Healthcare Products Regulatory Agency approved Beyonttra for ATTR-CM in the UK in April 2025.
• The company holds $645,942 thousand in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Domestic research and experimental expenditures are no longer capitalized as of September 30, 2025, following the enactment of the OBBB in July 2025, leading to a reversal of previously recognized domestic current tax.

Sentiment

Score: 6

Explanation: While the company achieved significant regulatory approvals for Attruby/Beyonttra and generated substantial product revenue, leading to a large increase in total revenue, the net losses have also significantly widened. The increase in SG&A expenses for commercialization is expected but contributes to the losses. Strategic financing and royalty sales provide liquidity, but the overall financial health still shows a substantial accumulated deficit. The reprioritization of R&D programs is a positive step towards efficiency.

Positives

• Total revenues, net, increased significantly by $117,968 thousand for the three months ended September 30, 2025, and $131,878 thousand for the nine months ended September 30, 2025, primarily driven by net product revenue from Attruby.
• Successful commercial launch of Attruby in the U.S. following FDA approval in November 2024, generating $216,351 thousand in net product revenue for the nine months ended September 30, 2025.
• Regulatory approvals for Beyonttra (acoramidis) in the EU (February 2025), Japan (March 2025, with pricing in May 2025), and the UK (April 2025), expanding market reach.
• Achieved a $75,000 thousand regulatory milestone payment from Bayer in February 2025 upon EC approval of Beyonttra.
• Achieved a $30,000 thousand regulatory milestone payment from Alexion in June 2025 following pricing approval in Japan for Beyonttra.
• Secured $300,000 thousand in cash from a Royalty Interest Purchase and Sale Agreement in June 2025, selling certain royalty rights on acoramidis net sales in the EU.
• Strategic financing through the issuance of $575,000 thousand in 2031 Notes, used in part to repay the Amended Financing Agreement term loan.
• Research and Development expenses decreased by $40,575 thousand for the nine months ended September 30, 2025, due to program reprioritization.
• Maintained a strong cash position with $645,942 thousand in cash, cash equivalents, and marketable securities as of September 30, 2025.

Negatives

• Net loss increased to $(184,937) thousand for the three months ended September 30, 2025, from $(164,254) thousand in the prior year.
• Net loss significantly increased to $(538,303) thousand for the nine months ended September 30, 2025, from $(275,958) thousand in the prior year.
• Selling, General and Administrative (SG&A) expenses increased substantially by $178,991 thousand for the nine months ended September 30, 2025, primarily due to commercial launch activities.
• Incurred a $21,155 thousand loss on extinguishment of debt in February 2025 related to the repayment of the Amended Financing Agreement.
• Noncash interest expense on deferred royalty obligations amounted to $(86,460) thousand for the nine months ended September 30, 2025.
• Net loss from equity method investments increased to $(51,579) thousand for the nine months ended September 30, 2025, from $(14,488) thousand in the prior year.
• Accumulated deficit grew to $(3,628,331) thousand as of September 30, 2025.
• Cash, cash equivalents, and marketable securities decreased to $645,942 thousand from $681,101 thousand at December 31, 2024.

Risks

• Increased scrutiny by the FDA and other regulatory agencies on advertising and promotional practices, particularly direct-to-consumer (DTC) advertising, could lead to significant liability if products are promoted unlawfully or for off-label uses.
• Disruptions to the operations of the FDA, SEC, and other government agencies due to funding shortages, global health concerns, or changes in administration initiatives and staffing cuts could hinder timely review and approval of products, impacting business.
• Complete reliance on third parties for commercial manufacturing of Attruby and Beyonttra and for product candidates for clinical trials. Failure of these third parties to provide sufficient quantities, acceptable quality, or reasonable prices could harm the business.
• Dependence on single-source suppliers for drug substance and drug product for certain candidates and commercial products. Loss of these suppliers or their failure to supply could materially and adversely affect the business, leading to delays or curtailment of sales/development.
• Substantial uncertainty regarding how the new U.S. Presidential Administration (2025) will modify or revise FDA requirements and policies, potentially creating a more challenging or costly environment for therapeutic product development.
• Potential for shortages in the supply of Attruby or other approved product candidates, which could materially impact results.
• Products and product candidates may compete with other marketed drugs for access to manufacturing facilities.
• Any performance failure by existing or future manufacturers could delay clinical development, marketing approval, or commercialization.
• Current and anticipated future dependence on others for manufacturing may adversely affect future profit margins and ability to commercialize products on a timely and competitive basis.
• The company expects to incur operating and net losses for several years and may require additional funding, which may not be available on acceptable terms or at all.
• Ability to generate product revenue sufficient to achieve profitability depends heavily on the success of the commercialization strategy for acoramidis and other product candidates.
• May not realize the anticipated efficiencies and other benefits of past and future restructuring initiatives.
• Inherent unpredictability of preclinical and clinical development, with timelines and costs differing materially from expectations due to various factors.
• Inflationary factors, such as increases in raw material costs, clinical supplies, interest rates, and overhead costs, may adversely affect operating results.

Future Outlook

The company expects to continue incurring operating and net losses for at least the next several years as it funds drug development and discovery efforts and prepares for commercial launches of late-stage programs. Future revenue is anticipated to be primarily generated from recurring net product revenue from Attruby and significant royalty revenue from commercial sales of Beyonttra by partners in the EU, Japan, and UK. The company will continue to assess operating costs and expenses and its cash position, making appropriate adjustments to its operating plan as needed. Current cash, cash equivalents, and marketable securities are expected to fund operations for at least the next 12 months based on current operating plans and financial forecasts.

Management Comments

• Our team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.
• We expect to continue to incur operating and net losses for at least the next several years.
• We expect that these initiatives, including restructuring, will reduce our operating expenses.
• We expect our cash, cash equivalents and marketable securities will fund our operations for at least the next 12 months from the date of filing of this Quarterly Report on Form 10-Q based on current operating plans and financial forecasts.

Industry Context

BridgeBio operates in the biopharmaceutical industry, specializing in transformative medicines for genetic diseases. Its strategy involves translating academic research into products, leveraging scientific advances in genomics and molecular biology. The company's successful commercialization of Attruby/Beyonttra and advancement of its late-stage pipeline (infigratinib for achondroplasia, encaleret for ADH1, BBP-418 for LGMD2I/R9) positions it within the rare disease and precision medicine segments. The company utilizes a hybrid model of wholly-owned subsidiaries, controlled entities, and strategic partnerships (e.g., Bayer, Kyowa Kirin, Alexion) for risk sharing and market access, a common practice in the biopharma sector. The impact of the 'One Big Beautiful Bill Act (OBBB)' on domestic research and experimental expenditures highlights the significant influence of government policy on the R&D-intensive biopharma industry.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• May become party to legal proceedings and claims arising in the ordinary course of business in the future.

Related Party Transactions

• Third-party investors providing financing to GondolaBio include an entity owned by Neil Kumar, the Company's Chief Executive Officer.
• Subsequent to June 27, 2025, KKR & Co. Inc., a beneficial holder of the Company's common equity, acquired a majority ownership interest in HealthCare Royalty Management, LLC (HCRx), making HCRx a related party.
• Deferred royalty obligations under the Royalty Purchase Agreement include related party amounts of $203,128 thousand for carrying value and $(1,886) thousand for unamortized debt discount and issuance costs as of September 30, 2025.
• Noncash interest expense on deferred royalty obligations includes related party amounts of $(5,383) thousand for the three months ended September 30, 2025, and $(5,560) thousand for the nine months ended September 30, 2025.
• Other current liabilities include a related party amount of $1,647 thousand as of September 30, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings (ATM program) and the impact of net losses on equity value, balanced by potential future value creation from commercialized products and pipeline advancements.
• Employees are affected by restructuring initiatives, which include workforce reductions, while stock-based compensation plans and the ESPP offer incentives.
• Customers (patients) benefit from new treatment options for ATTR-CM through the commercialization of Attruby/Beyonttra.
• Partners (Bayer, Kyowa Kirin, Alexion) continue to engage in collaborations and receive royalty payments based on product sales.
• Creditors (noteholders, royalty purchasers) are impacted by the company's significant debt obligations and deferred royalty payments.

Next Steps

• Continue funding drug development and discovery efforts.
• Drive commercialization of Attruby in the U.S.
• Support commercial sales of Beyonttra by Bayer and Alexion in the EU, Japan, and UK.
• Advance late-stage product candidates: low-dose infigratinib for achondroplasia, encaleret for ADH1, and BBP-418 for LGMD2I/R9.
• Continue to evaluate research and development pipelines and restructure the business to streamline costs and expenses.
• Explore business opportunities to partner, divest, or delay certain research and development programs.
• Assess operating costs and expenses and cash position, making appropriate adjustments to the operating plan.
• Maricel M. Apuli's trading plan indicates potential sale of shares under ESPP on February 13, 2026, and August 15, 2026.

Key Dates

Recommendation

BridgeBio Pharma demonstrates strong progress in commercializing Attruby/Beyonttra, evidenced by significant revenue growth and multiple global regulatory approvals. This indicates successful execution on key pipeline assets. However, the company continues to report substantial net losses, driven by high selling, general, and administrative expenses associated with commercialization efforts. While strategic financing and royalty sales have bolstered liquidity, the accumulated deficit remains large, and the company anticipates continued losses. The reprioritization of R&D programs is a positive step towards efficiency, but the overall financial picture is mixed. Investors should hold to observe the trajectory of Attruby/Beyonttra sales, the impact of R&D reprioritization on profitability, and the company's ability to manage its significant debt and royalty obligations while advancing its pipeline. The stock presents both significant upside potential from successful product launches and considerable financial risks.

Keywords

Biopharmaceutical, Genetic diseases, Attruby, Beyonttra, Acoramidis, ATTR-CM, Transthyretin amyloid cardiomyopathy, Infigratinib, Achondroplasia, Encaleret, ADH1, BBP-418, LGMD2I/R9, SEC filing, Q3 2025 earnings, Drug development, Clinical trials, FDA approval, European Commission approval, Japan approval, UK approval, Convertible notes, Royalty financing, Biotech, Pharmaceuticals